These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 17137902

  • 1. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents.
    Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED.
    J Pediatr; 2006 Dec; 149(6):833-6. PubMed ID: 17137902
    [Abstract] [Full Text] [Related]

  • 2. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 3. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
    Pontikaki I, Gerloni V, Gattinara M, Luriati A, Salmaso A, De Marco G, Teruzzi B, Valcamonica E, Fantini F.
    Reumatismo; 2006 Aug; 58(1):31-8. PubMed ID: 16639486
    [Abstract] [Full Text] [Related]

  • 4. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
    Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED.
    Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience.
    Baszis K, Garbutt J, Toib D, Mao J, King A, White A, French A.
    Arthritis Rheum; 2011 Oct; 63(10):3163-8. PubMed ID: 21702011
    [Abstract] [Full Text] [Related]

  • 6. [Anti-TNFalpha treatment of juvenile uveitis].
    Fledelius HC, Nielsen SM, Nissen KR, Pedersen FK, Zak MS.
    Ugeskr Laeger; 2007 Apr 02; 169(14):1309-12. PubMed ID: 17437693
    [Abstract] [Full Text] [Related]

  • 7. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May 02; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr 02; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 9. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
    de Oliveira SK, de Almeida RG, Fonseca AR, Rodrigues MC, Sztajnbok F, Diniz C.
    Acta Reumatol Port; 2007 Apr 02; 32(2):139-50. PubMed ID: 17572652
    [Abstract] [Full Text] [Related]

  • 10. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
    Schmeling H, Horneff G.
    Rheumatology (Oxford); 2005 Aug 02; 44(8):1008-11. PubMed ID: 15855187
    [Abstract] [Full Text] [Related]

  • 11. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK.
    J Rheumatol; 2007 May 02; 34(5):1146-50. PubMed ID: 17343318
    [Abstract] [Full Text] [Related]

  • 12. Risk factors and longterm outcome of juvenile idiopathic arthritis-associated uveitis in Switzerland.
    Bolt IB, Cannizzaro E, Seger R, Saurenmann RK.
    J Rheumatol; 2008 Apr 02; 35(4):703-6. PubMed ID: 18278829
    [Abstract] [Full Text] [Related]

  • 13. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 02; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 14. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS.
    Arthritis Rheum; 2005 Feb 15; 53(1):18-23. PubMed ID: 15696578
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and outcome of juvenile idiopathic arthritis-associated uveitis and relation to articular disease.
    Grassi A, Corona F, Casellato A, Carnelli V, Bardare M.
    J Rheumatol; 2007 May 15; 34(5):1139-45. PubMed ID: 17343317
    [Abstract] [Full Text] [Related]

  • 16. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis.
    Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED.
    Arthritis Rheum; 2010 Jun 15; 62(6):1824-8. PubMed ID: 20178126
    [Abstract] [Full Text] [Related]

  • 17. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment.
    Kakkassery V, Mergler S, Pleyer U.
    Curr Eye Res; 2010 Aug 15; 35(8):751-6. PubMed ID: 20673052
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood].
    Heiligenhaus A, Horneff G, Greiner K, Mackensen F, Zierhut M, Foeldvari I, Michels H.
    Klin Monbl Augenheilkd; 2007 Jun 15; 224(6):526-31. PubMed ID: 17594625
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.